Since the 2019 National Lipid Association (NLA) Scientific Statement on Use of Lipoprotein
(a) in Clinical Practice was issued, accumulating epidemiological data have clarified the …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Atherosclerotic cardiovascular diseases (ASCVD) are a very important cause of premature
death. The most important risk factor for ASCVD is lipid disorders. The incidence of lipid …

Background Data support lipoprotein (a)(Lp [Lp (a)]) being a risk factor for atherosclerotic
cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that …

Background and aims The LPA gene encodes apolipoprotein (a), a key component of Lp (a),
a potent risk factor for cardiovascular disease with no specific pharmacotherapy. Here we …

Lipoprotein (a)(Lp (a)) is a complex circulating lipoprotein, and increasing evidence has
demonstrated its role as a risk factor for atherosclerotic cardiovascular disease (ASCVD) …

Randomized controlled trials (RCTs) show that decreases in low-density lipoprotein
cholesterol (LDL-C) by the use of statins cause a significant reduction in the development of …

Genome wide association, epidemiological, and clinical studies have established high
lipoprotein (a)[Lp (a)] as a causal risk factor for atherosclerotic cardiovascular disease …

Novel bio-therapeutic agents that harness the properties of small, non-coding nucleic acids
hold great promise for clinical applications. These include antisense oligonucleotides that …

Lipoprotein (a)(Lp (a)) molecule includes two protein components: apolipoprotein (a) and
apoB100. The molecule is the main transporter of oxidized phospholipids (OxPL) in plasma …